Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
EMA granted PRIority MEdicines (PRIME) designation to DNX-2401 from DNAtrix to treat recurrent glioblastoma. The company said in “the coming weeks” it will begin a Phase II trial evaluating DNX-2401 i...